Hyperfine, Inc. (HYPR)
0.8375
+0.02
(+2.98%)
USD |
NASDAQ |
Sep 28, 16:00
0.8375
0.00 (0.00%)
After-Hours: 20:00
Hyperfine Research and Development Expense (TTM) : 15.58M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.58M |
| March 31, 2026 | 16.26M |
| December 31, 2025 | 17.45M |
| September 30, 2025 | 18.73M |
| June 30, 2025 | 20.55M |
| March 31, 2025 | 21.97M |
| December 31, 2024 | 22.50M |
| September 30, 2024 | 23.36M |
| June 30, 2024 | 23.23M |
| March 31, 2024 | 22.60M |
| Date | Value |
|---|---|
| December 31, 2023 | 22.49M |
| September 30, 2023 | 21.75M |
| June 30, 2023 | 23.35M |
| March 31, 2023 | 25.28M |
| December 31, 2022 | 28.16M |
| September 30, 2022 | 31.83M |
| June 30, 2022 | 30.93M |
| March 31, 2022 | 29.70M |
| December 31, 2021 | 25.84M |
| September 30, 2021 | 20.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Abbott Laboratories | 3.128B |
| AngioDynamics, Inc. | 29.45M |
| Alphatec Holdings, Inc. | 76.69M |
| AtriCure, Inc. | 94.05M |
| Baxter International, Inc. | 480.00M |